Document Detail

Chromium can reduce the mutagenic effects of benzo[a]pyrene diolepoxide in normal human fibroblasts via an oxidative stress mechanism.
MedLine Citation:
PMID:  9729358     Owner:  NLM     Status:  MEDLINE    
The interaction of multiple carcinogens on human cells has not been extensively examined. This study reports the results of experiments in which normal human fibroblasts were exposed to both benzo[a]pyrene diolepoxide (BPDE) and potassium dichromate. The effect of four different treatment protocols on the cloning ability of the cells and the mutant frequency of the HPRT gene was determined. The combined treatment of both carcinogens caused a slightly greater than additive decrease in the cloning ability of the cells when compared to cells treated with the individual carcinogens. The result was the same regardless of the treatment protocol used in the experiment. The results of the mutant frequency experiments, however, varied dramatically with the protocol employed. The mutant frequency in cells which were simultaneously treated with both carcinogens was dramatically reduced from the mutant frequency found when cells were treated with BPDE alone. This antagonistic effect was not present when cells were either pretreated with potassium dichromate prior to BPDE or incubated with potassium dichromate following BPDE treatment. The observed antagonistic effect was the result of oxidative stress produced by chromium since it was completely or nearly completely reversed by the addition of either vitamin E or catalase to the cultures.
Y Tesfai; D Davis; D Reinhold
Related Documents :
6394768 - Bacterial and mammalian cell mutagenesis, sister-chromatid exchange, and mouse lung ade...
6802508 - Retinol (vitamin a) inhibits sister chromatid exchanges and cell cycle delay induced by...
10558908 - Function of human factor h and i on xenosurface.
2833898 - Intracellular transport of vsv g protein occurs in cells lacking a nuclear envelope.
1315898 - Spectroscopic and biological studies of spin-labeled tetracycline.
23992308 - Indometacin ameliorates high glucose-induced proliferation and invasion via modulation ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Mutation research     Volume:  416     ISSN:  0027-5107     ISO Abbreviation:  Mutat. Res.     Publication Date:  1998 Aug 
Date Detail:
Created Date:  1998-09-28     Completed Date:  1998-09-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0400763     Medline TA:  Mutat Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  159-68     Citation Subset:  IM    
Copyright Information:
Copyright 1998 Elsevier Science B.V.
Departments of Chemistry and Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide / toxicity*
Antimutagenic Agents / pharmacology*
Cells, Cultured
Chromium / pharmacology*
Colony-Forming Units Assay
Drug Interactions
Hypoxanthine Phosphoribosyltransferase / genetics
Mutagenicity Tests
Mutagens / toxicity*
Oxidative Stress
Reactive Oxygen Species / metabolism
Reg. No./Substance:
0/Antimutagenic Agents; 0/Mutagens; 0/Reactive Oxygen Species; 55097-80-8/7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; 7440-47-3/Chromium; EC Phosphoribosyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neurop...
Next Document:  Immobility and flight associated with antinociception produced by activation of the ventral and late...